COMP <GO>
ADPT vs IOVA // DIVIDEND YIELD & FCF PAYOUT SAFETY
Adaptive Biotechnologies Corporation (NASDAQ) VS. Iovance Biotherapeutics Inc. (NASDAQ) • 15-METRIC TALLY: ADPT 10
— IOVA 2
■ METRIC PARITY
LAST: $25.06 (-5.93%) • MKT CAP: $4.00B
dividend-safety
0.00%
LAST: $8.02 (-5.42%) • MKT CAP: $3.63B
dividend-safety
0.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ADPT VS. IOVA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ADPT | IOVA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 74.20% | 34.30% | +39.90 | ADPT | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -12.50% | -35.00% | +22.50 | ADPT | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -1.09% | -7.76% | +6.67 | ADPT | /fcf-yield <GO> |
| Operating Margin | -20.60% | -60.00% | +39.40 | ADPT | /operating-margins <GO> |
| Net Profit Margin | -21.50% | -60.00% | +38.50 | ADPT | /net-margins <GO> |
| Revenue Growth (YoY) | 54.80% | 60.60% | -5.80 | IOVA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety ACTIVE | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.32 | 7.08 | -0.76 | IOVA | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 4/9 | +2.00 | ADPT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 43.7 | 31.8 | +11.90 | ADPT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.01 | 0.99 | +0.02 | ADPT | /macro-sensitivity <GO> |
| Forward P/E Multiple | 26.0x | 33.0x | -7.00 | ADPT | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.00B | $3.63B | $366.6M | ADPT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ADPT REV | IOVA REV | ADPT GROSS % | IOVA GROSS % | ADPT FCF | IOVA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $277.0M | $263.5M | 74.2% | 34.3% | -$48.9M | -$336.2M |
| FY 2024 | $179.0M | $164.1M | 59.7% | 43.2% | -$98.9M | -$364.0M |
| FY 2023 | $170.3M | $1.2M | — | — | -$164.0M | -$361.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ADPT // BETA 1.01
IOVA // BETA 0.99